Marconi Medical Systems Gets FDA Clearance for Large-Bore Oncology CT Scanner

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 11
Volume 9
Issue 11

CLEVELAND-Marconi Medical Systems has received 510k clearance from the FDA to market its new ACQSIM CT scanner that addresses the special needs of oncology CT simulation and planning.

CLEVELAND—Marconi Medical Systems has received 510k clearance from the FDA to market its new ACQSIM CT scanner that addresses the special needs of oncology CT simulation and planning.

The ACQSIM CT scanner is designed with an 85-cm large bore, to simplify planning difficult cases, including breast, Hodgkin’s lymphoma, and large patients.

The acQsim system includes a high-precision localization and marking system and a virtual simulator that yield digitally composited and/or reconstructed radiographs that exceed the requirements of conformal and high-precision radiotherapy delivery, the company said.

The footprint of the new scanner is the same as that of standard 70-cm diagnostic CTs and is designed to fit into rooms that currently house a conventional simulator or CT scanner.

Several sites will be installed in 2000, the company said, with general product release scheduled for the spring of 2001.

Recent Videos
Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.
2 experts are featured in this video
2 experts are featured in this video
2 experts are featured in this video
4 KOLs are featured in this series.
Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
An 80% sensitivity for lung cancer was observed with the liquid biopsy, with high sensitivity observed for early-stage disease, as well.
Related Content